Martine A Rothblatt sold $4.8M of UTHR
Chairperson & CEO at UNITED THERAPEUTICS Corp. 9,500 shares at an average of $502.35, traded Sep 10, 2026, filed Sep 11, 2026.
Score components
- +25RoleCEO
- +25Trade size$4.8M at market
- 0Share of holdings soldSold 2.8% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001106578-26-000139, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | MOption exercise Common Stockindirect: by Trust10b5-1 | +9,500 | $117.76 | $1.1M | 333,943 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -120 | $498.44 | $60k | 333,823 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,788 | $499.75 | $894k | 332,035 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,372 | $500.58 | $687k | 330,663 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -2,244 | $501.88 | $1.1M | 328,419 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,536 | $502.80 | $772k | 326,883 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -578 | $503.76 | $291k | 326,305 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -702 | $505.03 | $355k | 325,603 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -600 | $505.94 | $304k | 325,003 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -280 | $506.76 | $142k | 324,723 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -280 | $508.80 | $142k | 324,443 | 31 d ago |
| Sep 10, 2026 | MOption exercise Stock Optionderivativeindirect: by Trust10b5-1 | -9,500 | $0.00 | $0 | 461,410 | 31 d ago |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.